2021 年 43 巻 4 号 p. 411-414
Introduction. Brentuximab vedotin (BV) is a CD30-directed antibody-drug conjugate. It is indicated for the treatment of CD30-expressing malignant lymphomas, such as CD30-expressing Hodgkin's lymphoma. Detailed case reports of BV-induced lung injuries are rare. We herein report a case of drug-induced lung injury caused by BV. Case. The patient was an 82-year-old Japanese woman who had been diagnosed with diffuse large B-cell lymphoma. BV was used as third-line chemotherapy for relapsed CD30-positive lymphoma. Fifteen days after the third BV infusion, the patient experienced dyspnea on exertion. Chest computed tomography showed bilateral diffuse ground-glass opacities. Bronchoalveolar lavage revealed an increase in the number of lymphocytes (52%), and a transbronchial lung biopsy confirmed the presence of interstitial fibrosis associated with lymphocytic infiltration. She was diagnosed with BV-induced lung injury based on the temporal association between the use of BV and the development of lung injury, recovery following drug discontinuation, and the exclusion of all other possible causes. Conclusion. We herein report a case of drug-induced lung injury caused by BV. Bronchoscopy should be performed to rule out any other diseases when diagnosing drug-induced lung injury caused by BV. In addition, the clinical course should be carefully monitored in such cases.
